We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





COVID-19 Molecular Diagnostics Fueling Growth of Global Infectious Disease In-Vitro Diagnostics Market

By LabMedica International staff writers
Posted on 30 Apr 2021
Print article
Illustration
Illustration
The global infectious disease in-vitro diagnostics market is projected to record promising growth over the 2020-2030 period on back of the rising prevalence of infectious diseases around the world, particularly COVID-19.

These are the latest findings of TMR Research (San Francisco, CA, USA), a provider of customized market research and consulting services.

Infectious disease in-vitro diagnostic tests perform the function of detecting and identifying the specific infectious agent to establish its origin and enable healthcare professionals to provide the ideal treatment to a patient. These tests can also help in overcoming potential epidemics. This is acting as a vital growth generator for the infectious disease in-vitro diagnostics market. The increasing incidences of infectious diseases and the growing need to tackle them at an early stage have led to tremendous advancements in terms of diagnostics. Infectious disease in-vitro diagnostics is one of them. Thus, this will bring good growth opportunities for the infectious disease in-vitro diagnostics market.

The overwhelming use of infectious disease in-vitro diagnostics in point-of-care testing, central laboratories and others will create immense growth prospects for the market. The growing influence of infectious disease in-vitro diagnostics in detecting a variety of infections such as respiratory viruses, Chlamydia, HPV, Gonorrhea, Clostridium Difficile, MRSA, Streptococcus, Hepatitis B, HIV, Hepatitis C, COVID-19, and others will serve as a vital growth-generator.

The COVID-19 pandemic has wreaked havoc across the globe due to the rising transmission rates and fatality rates. The most efficient way to decrease the mortality rate and prevent infecting others is an intense focus on testing. For COVID-19 testing, RT-PCR (real-time reverse transcription-polymerase chain reaction) is regarded as a gold standard. This testing method is the clinical gold standard for the etiological diagnosis of COVID-19 in which viral DNA is directly detected. RT-PCR tests are being considered as the best option for COVID-19 testing around the world. The growing popularity of these testing methods will create huge growth prospects for the infectious disease in-vitro diagnostics market.

Manufacturers in the infectious disease in-vitro diagnostics market are developing kits that are easier for home use. These kits are designed for home-testing and treatments. Self-testing kits are useful for early diagnosis and consistent patient monitoring. They are also important for curbing costs. Hence, the rising demand for self-testing kits is directly proportional to the growth of the infectious disease in-vitro diagnostics market.

Geographically, North America will continue to dominate the global infectious disease in-vitro diagnostics market with the largest share between 2020 and 2030 on the back of the rising COVID-19 infections across the region. However, the Asia Pacific infectious disease in-vitro diagnostics market is expected to record the fastest growth during this period.

Related Links:
TMR Research

New
Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Benchtop Cooler
PCR-Cooler & PCR-Rack
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.